FMR LLC & Abigail Johnson Disclose 15.0% of Beam Therapeutics (BEAM)

Rhea-AI Filing Summary

Filing: Amendment No. 9 to Schedule 13G filed for BEAM THERAPEUTICS INC (CUSIP 07373V105) reporting a beneficial ownership position.

Key facts: FMR LLC and Abigail P. Johnson report aggregate beneficial ownership of 15,083,498.08 shares (15.0%). FMR LLC reports sole voting power of 15,073,316 and sole dispositive power of 15,083,498.08; shared powers are 0. Abigail P. Johnson reports sole dispositive power of 15,083,498.08 and no voting power. The "Date of Event Which Requires Filing" is 06/30/2025 and the signature date is 08/05/2025. Item 10 certifies the securities were not acquired to change or influence control. Exhibits referenced: Exhibit 99 (13d-1(k)(1) agreement) and Exhibit 24 (power of attorney).

Positive

• Transparent disclosure: Amendment No. 9 reports detailed beneficial ownership figures for FMR LLC and Abigail P. Johnson.
• Material stake disclosed: Aggregate position of 15,083,498.08 shares (15.0%) is explicitly stated.
• Specific voting/dispositive powers provided: FMR LLC reports 15,073,316 sole voting power and 15,083,498.08 sole dispositive power.

Negative

• None.

Insights

Financial Analyst

FMR and Abigail Johnson report a 15.0% position in BEAM; routine disclosure with no stated control intent.

The Schedule 13G/A discloses an aggregate beneficial ownership of 15,083,498.08 shares (15.0%), with FMR LLC holding sole voting power of 15,073,316 and sole dispositive power of 15,083,498.08. The filing is dated with the event on 06/30/2025 and signed 08/05/2025. Item 10 explicitly states the holdings were not acquired to influence control, consistent with a passive 13G filing. For investors, the materiality is the size of the block (15.0%), which is large enough to be relevant to shareholder dynamics but the filing contains no transaction, change in intent, or timelines.

Corporate Governance Expert

Material ownership block reported; filing under Rule 13d-1(b)/(c) indicates passive status but warrants monitoring.

The disclosure identifies FMR LLC as a reporting person classified as HC and Abigail P. Johnson as IN, each tied to the same aggregate position of 15,083,498.08 shares (15.0%). The filing references a 13d-1(k)(1) agreement (Exhibit 99) and a power of attorney (Exhibit 24), which govern reporting and signature authority. While the filing affirms no intent to influence control per Item 10, the size of the stake is material to governance considerations and should be tracked for any future amendments or Schedule 13D activity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

BEAM THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

07373V105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 07373V105

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,073,316.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,083,498.08
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,083,498.08

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 07373V105

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,083,498.08
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,083,498.08

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BEAM THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 26 Landsdowne Street,Cambridge,MA,US,02139
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 07373V105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15083498.08
(b)	Percent of class: 15.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 15083498.08
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BEAM THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of BEAM THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2025

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:	08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many BEAM shares does FMR LLC report owning?

FMR LLC reports beneficial ownership of 15,083,498.08 shares, representing 15.0% of the class.

What voting and dispositive powers are disclosed by FMR LLC?

FMR LLC discloses sole voting power of 15,073,316 shares and sole dispositive power of 15,083,498.08 shares; shared powers are 0.

What does Abigail P. Johnson report in this filing?

Abigail P. Johnson reports aggregate beneficial ownership of 15,083,498.08 shares (15.0%) with sole dispositive power of 15,083,498.08 and no voting power.

When is the event date and when was the filing signed?

The "Date of Event Which Requires Filing" is 06/30/2025 and the filing is signed on 08/05/2025.

Does the filing state an intent to influence control of Beam Therapeutics (BEAM)?

No. Item 10 certifies that the securities were not acquired and are not held to change or influence control of the issuer.